Area-level socioeconomic status is positively correlated with glioblastoma incidence and prognosis in the United States

Front Oncol. 2023 Mar 17:13:1110473. doi: 10.3389/fonc.2023.1110473. eCollection 2023.

Abstract

In the United States, an individual's access to resources, insurance status, and wealth are critical social determinants that affect both the risk and outcomes of many diseases. One disease for which the correlation with socioeconomic status (SES) is less well-characterized is glioblastoma (GBM), a devastating brain malignancy. The aim of this study was to review the current literature characterizing the relationship between area-level SES and both GBM incidence and prognosis in the United States. A query of multiple databases was performed to identify the existing data on SES and GBM incidence or prognosis. Papers were filtered by relevant terms and topics. A narrative review was then constructed to summarize the current body of knowledge on this topic. We obtained a total of three papers that analyze SES and GBM incidence, which all report a positive correlation between area-level SES and GBM incidence. In addition, we found 14 papers that focus on SES and GBM prognosis, either overall survival or GBM-specific survival. Those studies that analyze data from greater than 1,530 patients report a positive correlation between area-level SES and individual prognosis, while those with smaller study populations report no significant relationship. Our report underlines the strong association between SES and GBM incidence and highlights the need for large study populations to assess SES and GBM prognosis to ideally guide interventions that improve outcomes. Further studies are needed to determine underlying socio-economic stresses on GBM risk and outcomes to identify opportunities for intervention.

Keywords: ethnicity; glioblastoma; health disparities; public health; race; social determinants; socioeconomic status; survival.

Publication types

  • Review

Grants and funding

This work was funded by NIH/NINDS R01NS094199, R01NS092641, R01NS124081, VeloSano, Cleveland Clinic, Amy Post Foundation, and Case Comprehensive Cancer Center.